{"name":"ORIC Pharmaceuticals","slug":"oric-pharmaceuticals","ticker":"ORIC","exchange":"NASDAQ","domain":"oricpharma.com","description":"","hq":"South San Francisco, CA, USA","founded":0,"employees":"","ceo":"","sector":"Oncology / Drug Resistance","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-129468000,"cash":45669000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ORIC-533","genericName":"ORIC-533","slug":"oric-533","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ORIC-533","genericName":"ORIC-533","slug":"oric-533","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQWEpmc3RwRWNrSzRpT204OEI1aG9kX2JWbnNwWkNHZXRSWlE4Nl9PRWpWaHRQTEpsVGw2LUFuZ0c5ZlVrcE9aU29wZHA1WE5BMzFnUk90ZERrVV9DM2otRWJTUHBnek9GQWx0b1NET3p3OWFFbUxiVnM5V05Ybk9XNWhKeUVQeWVyZGtMaVQ2emlfcVpRaDFiZWU3bVlXczdCNEpNR0dBekQ2S0RfS3BHX1l0aXhpV3phTzRGVko5UGs4ZlE?oc=5","date":"2026-04-06","type":"trial","source":"msn.com","summary":"ORIC Pharma drops after early-stage trial data for prostate cancer therapy - msn.com","headline":"ORIC Pharma drops after early-stage trial data for prostate cancer therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOaWVsNHNMQVVrYXk0WXpNWVBEN1d0TC13WDRoVy0yZ3NzVXMwV1pWWTlSNUlUUXFMUVJsTHQwLXcyWFVtNks1cnU1TkNMZldCZ1NJWUhLQlVYUm5pVGo0QU9lSWRTejhsTUNvV2k5b25SbnItX2tJWHVqc0V2VThKSUdDOFJudGRrdDBzYnhvM1VIaE11dzVFOHBqVEZGWDd1UnhnZ3lqVC05ZmZhazdyYl9mdERYMENHeGhzVkFnMHZtbkNHTVhULWhYblpXdGpidVN2MTg2VXAtSW8?oc=5","date":"2026-04-02","type":"deal","source":"The Globe and Mail","summary":"Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI - The Globe and Mail","headline":"Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPYjZyZ3VWOUw0d3BiNzlidkNRVjFNc3MzVlk0bThreWd3OW9TRHdDTjR5dGVlc1lRblF1dWtZWi1ReU95SEk5VHNDVF9Qc1MxeDVPVWtxaFIwQWg0NFh1aU0tdkxMRl9wLXBGSm9RTUlZb2JqTU1aRG5GTm1aZzVnWF8wS1FZYVl3TkRfWV9kUHF3YUZhNnc?oc=5","date":"2026-04-01","type":"pipeline","source":"Investor's Business Daily","summary":"Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges - Investor's Business Daily","headline":"Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE85YmJ4Q0hBYXo0V3VLaFJQcFhhYUJlb0pWeFFSemJBUDFnMDh3ZkItM2hmTmc1UFdkUjZEb0k0aTg0VVoyejFoS015alVkWVJSQ3ZYaUZnWmVBZWVISGfSAWNBVV95cUxOU1h3Zy1WNWJ1QVFTSWRUcGMwXzNHbmx6ZjAwYjZmWWtCM2ZNWGJ6RFlOeHg1Ulc1REtLX3ZOTXNKRnI2eWhJSnU2SmVBa3RXMGhiNm9uaXI5V2JsRF9NWHh5ejg?oc=5","date":"2026-03-31","type":"pipeline","source":"Bitget","summary":"ORIC Pharma Fails to Surpass Expected Efficacy, Prompting \"Sell the News\" Decline as Results Align with, But Do Not Surpass, Forecasts - Bitget","headline":"ORIC Pharma Fails to Surpass Expected Efficacy, Prompting \"Sell the News\" Decline as Results Align with, But Do Not Surp","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-23","type":"deal","source":"simplywall.st","summary":"ORIC Cancer Pipeline Progress And Big Pharma Partnerships Reshape Risk Profile - simplywall.st","headline":"ORIC Cancer Pipeline Progress And Big Pharma Partnerships Reshape Risk Profile","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdFR2OExtX3V3bmNlaHBXQWpDNkZPREdJLVYxUFZUNktNRVdsVl8zV2FIVmFRRU5sUlZ5YTNDZ2pkVU95MUs2Y2hBRXJrUmg1dWUtQ2Q0UVo5WTRmUGgxZ2NKUGttTXl4ZkV3bUFPTFItcXRqTnFkdzQ0VWtnZnFtaXVGXzNuQWp5MUgwTkJNY2JjQVlfendMRUxEb2h5R0E4YkE?oc=5","date":"2025-12-03","type":"trial","source":"The Clinical Trial Vanguard","summary":"ORIC Pharma to Present Enozertinib Data in NSCLC at ESMO - The Clinical Trial Vanguard","headline":"ORIC Pharma to Present Enozertinib Data in NSCLC at ESMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNOTRnRndKWUZwY3VIeUJRZEtKRXZkQnQ1d1prVEhFWGhVbjhjcDhRekQ5LWJ2TkFXdFBTY3NQVEhNNENTUHRZTURQZWNDUUxFMDZhcEhqSkxKN0U2RUlWMTBMMnpwYk9mbV9IQnIyVFI0MTFqLVBrZXA0YkhlcnU0bTdkczMzaGpTMG13WFRDNl8?oc=5","date":"2025-12-02","type":"trial","source":"Yahoo Finance","summary":"ORIC Pharmaceuticals (ORIC) Valuation Check as New Phase 1b Enozertinib Lung Cancer Data Approaches - Yahoo Finance","headline":"ORIC Pharmaceuticals (ORIC) Valuation Check as New Phase 1b Enozertinib Lung Cancer Data Approaches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdEdNYzVDUmJ1bFBIUFYyQnlOYUlyYi1Xd0RzcC1YWmp6UVB0bFVLVFZlRlpwVXUtcWY4d2NRRGt2WVhWdHAwY0lrVFZtNEpxOW9GU2Yxd0JJZDV2LWpRbENrTV93bE5vUnBWYUpxOHRSX2xndmxrY01QTm9ndXRabnlIWFZiSGFzaHVJaTlLS25YckNPdDZSNTdNSTBteU5kbUh4U2VNQ0E?oc=5","date":"2025-11-17","type":"trial","source":"RTTNews","summary":"ORIC Pharma Surges Ahead With ORIC-944 And Enozertinib Data Momentum - RTTNews","headline":"ORIC Pharma Surges Ahead With ORIC-944 And Enozertinib Data Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOGZ0azlUZ0Zlam02TnFvZnJuZGtVVzBTUDJ3Z3dObkEwTk1MRGpMYkNHdGVJTUwzWTdFaE11X0VPUXJ2ZkdidE9HVDR3U3ljT0pYYWV6eXpyU3QtNS1UVy02UU54MklrNlA2SURqSEhHVUJZNTA4VDU5clBMekIzSTQwLU1uZGZzSXdSR3E1ampHS0hGOUgzMmVZT0JtMjYzQ3g5TUdKYkl6QQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Pharmaceutical Executive","summary":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize - Pharmaceutical Executive","headline":"Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbko0UGVnQjNGME5Wcmw4a0JSNWRlZzJETlVIUnlWaXlzYjhmV1czNUVxbzFOZ1BYZldNbGJ3ZDRCS3MzYmRsRFRLbC1WYVpHM3NmWjFOcFhzUDhIRncwdHkyNWh0ZEFQUG5tOWRfeFpFVTVkSkE2cEJFZmZ1a0xuQVBLY0Z1Q3FDanNkdmpzTGVhQXI2aW5CTXVwZjVhNWxrZW9qTjRKXzE?oc=5","date":"2025-08-13","type":"pipeline","source":"Fierce Biotech","summary":"Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs - Fierce Biotech","headline":"Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5UYUtjeF9vZUVHMHZTNWdtMlBwM2s1MXpZV3ZUNjhVR3NMNUVFWi1UQjV0Zlo2aVhnWnQ1TjRYSG9oRVlMRGdUaVRCUGtRTjk4a0dZ?oc=5","date":"2025-08-13","type":"pipeline","source":"FirstWord Pharma","summary":"Biotech layoffs: Fate, Generation Bio, ORIC trim teams and pipelines - FirstWord Pharma","headline":"Biotech layoffs: Fate, Generation Bio, ORIC trim teams and pipelines","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-129468000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":45669000,"cashHistory":[],"totalAssets":408890000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}